An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care
This acquisition is in line with Cipla's strategic imperative to augment the company's wellness portfolio for bringing about a shift from an illness to a wellness mindset.
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
Kaiser Permanente finds the Pfizer Covid-19 third dose vaccine protection against hospitalization from omicron wanes after 3 months
Key findings underscore the need for better control of glycemia, blood pressure and lipid parameters to prevent diabetes-related complications
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)